Lawrence M. Blatt Reports 5.1% Passive Stake in Aligos Therapeutics, Inc.

Lawrence M. Blatt filed a Schedule 13G on May 15, 2026, reporting a 5.1% stake in Aligos Therapeutics, Inc. (ALGS). As of the event date of March 31, 2026, Blatt beneficially owns 286,213 shares of Common Stock. This position is comprised of various holdings, including 3,251 shares held directly, 78,781 shares through the Lawrence M. Blatt Living Trust, and 4,904 shares via an IRA. Additionally, the total includes 12,206 shares from exercisable warrants and 185,591 shares underlying stock options that are exercisable within 60 days of the reporting date. Smaller amounts are also held in irrevocable trusts for Zachary David Blatt and Zoe Anne Blatt. The filing indicates a new significant ownership position compared to the previously reported 0.0% interest. The calculation is based on 5,388,223 shares of voting Common Stock outstanding as of May 1, 2026. Blatt maintains sole voting and dispositive power over all 286,213 shares.